PRGO,ALLO Stock Price and Quote

Dollar change -0.83
Percentage change -3.02	%

Peers: JNJ MRK PFE ABBV BMY LLY GSK NVS SAN AZN

| Held by: IJH VTI VB VBR VXF SDY SMIG REGL MDY DFAT

Index	-	P/E	-	EPS (ttm)	-1.27	Insider Own	0.48%	Shs Outstand	137.20M	Perf Week	-5.12%
Market Cap	3.67B	Forward P/E	8.28	EPS next Y	3.22	Insider Trans	-0.65%	Shs Float	136.82M	Perf Month	-2.77%
Enterprise Value	7.06B	PEG	-	EPS next Q	0.59	Inst Own	101.16%	Short Float	4.63%	Perf Quarter	3.69%
Income	-174.20M	P/S	0.85	EPS this Y	18.39%	Inst Trans	1.16%	Short Ratio	5.58	Perf Half Y	8.11%
Sales	4.34B	P/B	0.84	EPS next Y	5.92%	ROA	-1.61%	Short Interest	6.34M	Perf YTD	3.73%
Book/sh	31.81	P/C	8.94	EPS next 5Y	10.38%	ROE	-3.64%	52W High	30.93 -13.77%	Perf Year	-4.61%
Cash/sh	2.98	P/FCF	20.25	EPS past 3/5Y	-12.80% -	ROIC	-2.15%	52W Low	23.14 15.25%	Perf 3Y	-36.44%
Dividend Est.	1.17 (4.39%)	EV/EBITDA	10.04	Sales past 3/5Y	1.84% -1.99%	Gross Margin	36.36%	Volatility	2.08% 2.09%	Perf 5Y	-52.20%
Dividend TTM	1.13 (4.24%)	EV/Sales	1.63	EPS Y/Y TTM	-4290.31%	Oper. Margin	8.72%	ATR (14)	0.59	Perf 10Y	-85.94%
Dividend Ex-Date	Aug 29, 2025	Quick Ratio	1.28	Sales Y/Y TTM	-4.85%	Profit Margin	-4.02%	RSI (14)	41.77	Recom	2.00
Dividend Gr. 3/5Y	4.64% 6.05%	Current Ratio	2.36	EPS Q/Q	-256.04%	SMA20	-2.71%	Beta	0.47	Target Price	36.67
Payout	-	Debt/Eq	0.87	Sales Q/Q	-3.54%	SMA50	-1.27%	Rel Volume	1.38	Prev Close	27.50
Employees	8379	LT Debt/Eq	0.86	Earnings	Aug 06 BMO	SMA200	1.28%	Avg Volume	1.14M	Price	26.67
IPO	Dec 17, 1991	Option/Short	Yes / Yes	EPS/Sales Surpr.	6.04% -3.93%	Trades		Volume	1,566,199	Change	-3.02%

Date	Action	Analyst	Rating Change	Price Target Change
Jan-14-25	Downgrade	Argus	Buy → Hold
Jan-06-25	Downgrade	Piper Sandler	Overweight → Neutral	$34 → $27
Sep-24-24	Resumed	Jefferies	Hold	$50 → $30
Nov-17-23	Initiated	Piper Sandler	Overweight	$37
Mar-07-23	Initiated	Canaccord Genuity	Buy	$49
Sep-14-22	Upgrade	Argus	Hold → Buy	$46
Sep-06-22	Upgrade	Wells Fargo	Equal Weight → Overweight	$48 → $54
Oct-14-21	Upgrade	Raymond James	Mkt Perform → Outperform	$59
Sep-30-21	Upgrade	Jefferies	Hold → Buy	$45 → $63
Apr-07-21	Resumed	RBC Capital Mkts	Sector Perform	$51
Jan-06-21	Downgrade	RBC Capital Mkts	Outperform → Sector Perform	$59 → $49
Apr-17-20	Downgrade	Argus	Buy → Hold
Mar-24-20	Upgrade	JP Morgan	Neutral → Overweight	$57
Mar-20-20	Upgrade	SVB Leerink	Mkt Perform → Outperform	$54 → $52
Mar-18-20	Upgrade	RBC Capital Mkts	Sector Perform → Outperform	$58
Oct-11-19	Upgrade	Argus	Hold → Buy
Mar-20-19	Initiated	SunTrust	Hold
Nov-13-18	Downgrade	Berenberg	Buy → Hold
Aug-10-18	Reiterated	Stifel	Hold	$92 → $87
Jul-30-18	Downgrade	Argus	Buy → Hold

Show Previous Ratings

Jul-30-25 12:55PM	Perrigo Announces Quarterly Dividend (PR Newswire)
11:07AM	Perrigo to Report Q2 Earnings: What's in Store for the Stock? (Zacks)
Jul-29-25 08:30AM	Perrigo to Present at the Canaccord Genuity 45th Annual Growth Conference (PR Newswire)
Jul-25-25 09:40AM	Is Perrigo (PRGO) Stock Undervalued Right Now? (Zacks)
Jul-23-25 08:30AM	Perrigo to Release Second Quarter 2025 Financial Results on August 6, 2025 (PR Newswire)
12:33PM	Loading…
Jul-21-25 12:33PM	Analyst Report: Perrigo Company plc (Morningstar Research)
Jul-17-25 09:55AM	Wall Street Analysts Believe Perrigo (PRGO) Could Rally 35.36%: Here's is How to Trade (Zacks)
09:50AM	Why Perrigo (PRGO) is a Top Momentum Stock for the Long-Term (Zacks)
Jul-14-25 08:30AM	Perrigo Announces Agreement to Divest Dermacosmetics Business for up to 327 Million (PR Newswire)
Jul-09-25 09:40AM	Should Value Investors Buy Perrigo (PRGO) Stock? (Zacks)
Jul-02-25 09:15AM	Phibro Animal Health Corporation (PAHC) Hit a 52 Week High, Can the Run Continue? (Zacks)
Jul-01-25 04:30PM	Perrigo Announces Strategic Organizational Update to Drive Sustainable Growth and Performance (PR Newswire)
09:02AM	Good Start Dr. Brown's Launches 30-Day "Gentle Baby Formula Giveaway Contest" with a Generous Donation to Baby2Baby (PR Newswire)
Jun-23-25 09:40AM	Should Value Investors Buy Perrigo (PRGO) Stock? (Zacks)
Jun-20-25 09:48AM	These 3 Dividend Stocks Combine Strong Yields With Upside (MarketBeat)
09:55AM	Loading…
Jun-11-25 09:55AM	Does Perrigo (PRGO) Have the Potential to Rally 32.86% as Wall Street Analysts Expect? (Zacks)
Jun-06-25 11:31AM	Why Is Perrigo (PRGO) Down 3.1% Since Last Earnings Report? (Zacks)
09:40AM	Are Investors Undervaluing Perrigo (PRGO) Right Now? (Zacks)
Jun-04-25 08:30AM	Perrigo Announces Global Operations and Supply Chain Leadership Transition (PR Newswire)
May-23-25 09:17AM	Perrigo to Attend the Oppenheimer 25th Annual Consumer Growth & E-Commerce Conference (PR Newswire)
May-22-25 09:55AM	Wall Street Analysts Predict a 27.28% Upside in Perrigo (PRGO): Here's What You Should Know (Zacks)
May-21-25 09:40AM	Is Perrigo (PRGO) Stock Undervalued Right Now? (Zacks)
09:10AM	How to Maximize Your Retirement Portfolio with These Top-Ranked Dividend Stocks (Zacks)
May-14-25 10:55AM	Perrigo Company plc (PRGO): One of the Best Dividend Growth Stocks with High Yields (Insider Monkey)
May-13-25 09:50AM	Are You a Momentum Investor? This 1 Stock Could Be the Perfect Pick (Zacks)
09:16AM	Perrigo (PRGO) Reliance on International Sales: What Investors Need to Know (Zacks)
May-08-25 03:10AM	Perrigo Co PLC (PRGO) Q1 2025 Earnings Call Highlights: Strong Infant Formula Sales and Margin ... (GuruFocus.com)
May-07-25 06:43PM	Analyst Report: Perrigo Company plc (Morningstar Research) +7.01%
03:56PM	Is Perrigo Company plc (PRGO) the Best Mid-Cap Dividend Aristocrat to Invest in Now? (Insider Monkey)
02:14PM	Perrigo Company plc (PRGO) Q1 2025 Earnings Call Transcript (Seeking Alpha)
01:25PM	Loading…
01:25PM	Perrigo Q1 Earnings Beat Estimates, Revenues Decline Y/Y (Zacks)
09:30AM	Perrigo (PRGO) Reports Q1 Earnings: What Key Metrics Have to Say (Zacks)
07:45AM	Perrigo (PRGO) Q1 Earnings Beat Estimates (Zacks)
06:41AM	Perrigo: Q1 Earnings Snapshot (Associated Press Finance)
06:30AM	Perrigo Reports First Quarter 2025 Financial Results From Continuing Operations (PR Newswire)
May-05-25 09:54AM	Perrigo to Report Q1 Earnings: Is a Beat in Store for the Stock? (Zacks)
May-01-25 10:01AM	Prestige Consumer Healthcare (PBH) Reports Next Week: Wall Street Expects Earnings Growth (Zacks)
Apr-30-25 10:23AM	Perrigo Announces Quarterly Dividend (PR Newswire)
10:01AM	Perrigo (PRGO) Earnings Expected to Grow: Should You Buy? (Zacks)
Apr-24-25 06:21PM	Perrigo: Opill Shows Where The Company Wants To Be (Seeking Alpha)
Apr-23-25 04:47PM	Perrigo to Release First Quarter 2025 Financial Results on May 7, 2025 (PR Newswire)
Apr-21-25 10:29AM	Is Perrigo Co. PLC (PRGO) an Economically Resilient Company? (Insider Monkey)
Apr-10-25 10:40PM	Heartland Mid Cap Value Fund Q1 2025 Commentary (Seeking Alpha) -5.84%
11:36AM	Sanara MedTech (SMTI) Stock Jumps 8.1%: Will It Continue to Soar? (Zacks)
Apr-09-25 03:59PM	Trump's Tariffs Circle Pharma Industry: Who It Affects And How It May Play Out (Seeking Alpha) +5.38%
Apr-02-25 06:20AM	Is ProShares S&P MidCap 400 Dividend Aristocrats ETF (REGL) a Strong ETF Right Now? (Zacks)
Mar-22-25 12:31AM	Dividend Champion, Contender, And Challenger Highlights: Week Of March 23 (SeekingAlpha)
Mar-05-25 09:15AM	Investing in Perrigo (PRGO)? Don't Miss Assessing Its International Revenue Trends (Zacks)
Mar-04-25 01:41AM	Is Perrigo (PRGO) the Best Weight Loss Drug Stock to Buy According to Analysts? (Insider Monkey)
Mar-01-25 04:26PM	Why Perrigo Company plc (PRGO) Soared on Friday (Insider Monkey)
Feb-28-25 02:04PM	Analyst Report: Perrigo Company plc (Morningstar Research) +20.18%
07:15AM	Perrigo Provides Detailed Plan to Consumerize, Simplify and Scale its Unique Global Self-Care Platform at its Virtual Investor Day (PR Newswire)
Feb-27-25 07:30PM	Perrigo (PRGO) Q4 Earnings: Taking a Look at Key Metrics Versus Estimates (Zacks)
06:50PM	Perrigo (PRGO) Q4 Earnings Beat Estimates (Zacks)
05:49PM	Perrigo: Q4 Earnings Snapshot (Associated Press Finance)
05:20PM	Perrigo Reports Fourth Quarter & Fiscal Year 2024 Financial Results From Continuing Operations (PR Newswire)
Feb-26-25 04:05PM	Perrigo to Attend the UBS 2025 Global Consumer and Retail Conference (PR Newswire)
Feb-25-25 09:15AM	Countdown to Perrigo (PRGO) Q4 Earnings: A Look at Estimates Beyond Revenue and EPS (Zacks)
Feb-19-25 03:11PM	Perrigo Increases Quarterly Dividend by 5% (PR Newswire)
Feb-04-25 10:29AM	Opill extends mission of breaking down birth control barriers with launch of multi-state college tour and expansion of partnerships (PR Newswire)
Jan-31-25 09:00AM	Perrigo to Release Fourth Quarter and Fiscal Year 2024 Financial Results on February 27, 2025, Host Virtual Investor Day on February 28, 2025 (PR Newswire)
Jan-21-25 07:50AM	Heres White Falcon Capitals Investment Thesis for Perrigo Company plc (PRGO) (Insider Monkey)
Jan-06-25 08:00AM	Perrigo Expands its Scientific Office; Appoints Abbie Lennox as Executive Vice President and Chief Scientific Officer (PR Newswire)
Dec-06-24 11:31AM	Perrigo (PRGO) Up 5.6% Since Last Earnings Report: Can It Continue? (Zacks)
Nov-11-24 09:15AM	Perrigo (PRGO) International Revenue Performance Explored (Zacks)
Nov-07-24 02:09AM	Perrigo Co PLC (PRGO) Q3 2024 Earnings Call Highlights: Strategic Savings and EPS Growth Amid ... (GuruFocus.com)
Nov-06-24 04:51PM	Analyst Report: Perrigo Company plc (Morningstar Research) +7.73%
09:51AM	Perrigo Reports Third Quarter 2024 Financial Results From Continuing Operations (PR Newswire)
09:51AM	/C O R R E C T I O N -- Perrigo Company plc/ (PR Newswire)
09:30AM	Perrigo (PRGO) Q3 Earnings: How Key Metrics Compare to Wall Street Estimates (Zacks)
07:40AM	Perrigo (PRGO) Q3 Earnings and Revenues Lag Estimates (Zacks)
06:47AM	Perrigo: Q3 Earnings Snapshot (Associated Press Finance)
Nov-01-24 02:57PM	Perrigo Announces Quarterly Dividend (PR Newswire)
Oct-30-24 10:01AM	Perrigo (PRGO) Earnings Expected to Grow: What to Know Ahead of Next Week's Release (Zacks)
Oct-23-24 10:37AM	Perrigo Company plc (PRGO): Leading OTC Health Products with Strong Growth in Infant Formula (Insider Monkey)
09:00AM	Perrigo to Release Third Quarter 2024 Financial Results on November 6, 2024 (PR Newswire)
Oct-15-24 08:00AM	WNBA Star Napheesa Collier Joins Team Opill for Candid Conversations on Women's Health (PR Newswire)
Sep-26-24 08:30AM	Perrigo Announces Good Start and Dr. Browns Brand Partnership and Launch of Infant Formula Portfolio (PR Newswire)
Sep-17-24 04:48PM	PERRIGO ANNOUNCES THE CLOSING OF A SENIOR NOTES OFFERING BY ITS FINANCE SUBSIDIARY, PERRIGO FINANCE UNLIMITED COMPANY (PR Newswire)
Sep-13-24 07:00PM	Insider Sale: Director Katherine Doyle Sells 8,954 Shares of Perrigo Co PLC (GuruFocus.com)
Sep-12-24 09:00AM	PERRIGO ANNOUNCES THE PRICING OF A SENIOR NOTES OFFERING BY ITS FINANCE SUBSIDIARY, PERRIGO FINANCE UNLIMITED COMPANY (PR Newswire)
06:52AM	What Makes Perrigo Company plc (PRGO) an Attractive Bet? (Insider Monkey)
Sep-05-24 01:07AM	Perrigo Company plc (PRGO): Among the Best Mid-Cap Healthcare Stocks To Buy Now (Insider Monkey)
Sep-04-24 08:00AM	Perrigo Appoints Industry Veteran, Charles Atkinson, as Executive Vice President, General Counsel and Secretary (PR Newswire)
Sep-02-24 06:05PM	10 Best Mid-Cap Healthcare Stocks To Buy Now (Insider Monkey)
Aug-27-24 08:30AM	Perrigo to Attend the Piper Sandler Growth Frontiers Conference (PR Newswire)
Aug-19-24 08:30AM	Perrigo Appoints David Ball to the Newly Created Position of Executive Vice President and Chief Brand and Digital Officer (PR Newswire)
Aug-14-24 06:00AM	Stress on Shelvesthe Battle for Space in Store Aisles (The Wall Street Journal)
Aug-09-24 06:21AM	Perrigo recalls 16,500 cans of its infant formula (Reuters)
Aug-05-24 09:15AM	Interpreting Perrigo (PRGO) International Revenue Trends (Zacks)
Aug-02-24 02:16PM	Analyst Report: Perrigo Company plc (Morningstar Research)
10:42AM	Perrigo (PRGO) Beats on Q2 Earnings, Lags Sales, Cuts View (Zacks)
09:30AM	Compared to Estimates, Perrigo (PRGO) Q2 Earnings: A Look at Key Metrics (Zacks)
07:54AM	Perrigo Reaffirms FY24 Adj. EPS Guidance; Updates Sales Outlook (RTT News)
07:45AM	Perrigo (PRGO) Q2 Earnings Top Estimates (Zacks)
06:43AM	Perrigo: Q2 Earnings Snapshot (Associated Press Finance)
06:31AM	Perrigo Reports Second Quarter 2024 Financial Results From Continuing Operations (PR Newswire)
Aug-01-24 09:00AM	Perrigo Announces Quarterly Dividend (PR Newswire)
Jul-31-24 09:30AM	Perrigo to Attend the Canaccord Genuity 44th Annual Growth Conference (PR Newswire)
Jul-29-24 12:10PM	Perrigo (PRGO) to Report Q2 Earnings: Here's What to Expect (Zacks)

Perrigo Co. Plc is a pure-play self-care company provider of consumer self-care products and over-the-counter (OTC) health and wellness solutions that enhance individual well-being by empowering consumers to proactively prevent or treat conditions that can be self-managed. The company was founded by Luther Perrigo in 1887 and is headquartered in Dublin, Ireland.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Lockwood-Taylor Patrick	CEO	Jul 10 '25	Option Exercise	27.27	28,326	772,450	95,586	Jul 14 03:23 PM
Bezerra Eduardo Guarita	EVP & Chief Financial Officer	Jun 06 '25	Option Exercise	26.16	4,531	118,531	47,732	Jun 10 11:22 AM
Khoury Roberto	EVP and President of CSCI	Jun 06 '25	Option Exercise	26.16	10,868	284,307	7,888	Jun 10 11:22 AM
Doyle Katherine C.	Former Director	Jun 05 '25	Proposed Sale	26.21	11,159	292,477		Jun 05 03:47 PM
Brown Julia M	Director	May 14 '25	Option Exercise	26.01	9,904	257,603	12,788	May 16 11:53 AM
Alford Bradley A	Director	May 14 '25	Option Exercise	26.01	9,904	257,603	45,914	May 16 11:53 AM
O'Connor Donal	Director	May 14 '25	Option Exercise	26.01	9,904	257,603	35,391	May 16 11:52 AM
Parker Geoffrey M.	Director	May 14 '25	Option Exercise	26.01	9,904	257,603	33,666	May 16 11:52 AM
KINDLER JEFFREY B	Director	May 14 '25	Option Exercise	26.01	9,904	257,603	15,313	May 16 11:52 AM
Karaboutis Adriana	Director	May 14 '25	Option Exercise	26.01	9,904	257,603	32,383	May 16 11:52 AM
Manzone Albert	Director	May 14 '25	Option Exercise	26.01	9,904	257,603	17,309	May 16 11:52 AM
ASHFORD ORLANDO D	Director	May 14 '25	Option Exercise	26.01	12,380	322,004	28,113	May 16 11:51 AM
Parker Geoffrey M.	Director	May 12 '25	Buy	27.10	3,500	94,850	23,762	May 14 02:06 PM
Janish Ronald Craig	EVP, Gbl Ops & SC & CTO	Apr 04 '25	Option Exercise	26.31	2,707	71,221	36,373	Apr 08 08:10 AM
Bezerra Eduardo Guarita	EVP & Chief Financial Officer	Apr 04 '25	Option Exercise	26.31	6,370	167,595	45,655	Apr 08 08:10 AM
Schmelter Triona	EVP & President CSCA	Apr 04 '25	Option Exercise	26.31	5,733	150,835	8,310	Apr 08 08:10 AM
Lockwood-Taylor Patrick	CEO	Apr 04 '25	Option Exercise	26.31	17,835	469,239	73,708	Apr 08 08:10 AM
Willis Robert	EVP & CHRO	Apr 04 '25	Option Exercise	26.31	2,070	54,462	41,530	Apr 08 08:10 AM
Janish Ronald Craig	EVP, Gbl Ops & SC & CTO	Mar 07 '25	Option Exercise	27.76	2,941	81,642	40,745	Mar 10 08:07 PM
Janish Ronald Craig	EVP, Gbl Ops & SC & CTO	Mar 06 '25	Option Exercise	28.68	2,300	65,964	42,159	Mar 10 08:07 PM
Janish Ronald Craig	EVP, Gbl Ops & SC & CTO	Mar 10 '25	Sale	27.44	7,800	214,032	33,666	Mar 10 08:07 PM
Willis Robert	EVP & CHRO	Mar 07 '25	Option Exercise	27.76	2,163	60,045	39,745	Mar 10 08:07 PM
Willis Robert	EVP & CHRO	Mar 06 '25	Option Exercise	28.68	1,759	50,448	40,377	Mar 10 08:07 PM
Bezerra Eduardo Guarita	EVP & Chief Financial Officer	Mar 06 '25	Option Exercise	28.68	4,870	139,672	40,556	Mar 10 08:07 PM
Janish Ronald Craig	Officer	Mar 10 '25	Proposed Sale	27.44	7,800	214,032		Mar 10 02:45 PM
Brown Julia M	Director	Mar 05 '25	Option Exercise	29.47	5,548	163,500	5,548	Mar 07 10:21 AM
Andersen Svend	Officer	Mar 03 '25	Proposed Sale	29.53	27,000	797,369		Mar 03 03:51 PM
Andersen Svend	Former Officer	Mar 03 '25	Proposed Sale	30.30	17,343	525,416		Mar 03 10:48 AM
KINDLER JEFFREY B	Director	Dec 09 '24	Sale	28.27	17,598	497,495	5,409	Dec 10 10:45 AM
KINDLER JEFFREY B	Director	Dec 09 '24	Proposed Sale	28.27	17,598	497,426		Dec 09 04:24 PM
Schmelter Triona	EVP & President CSCA	Oct 04 '24	Option Exercise	24.93	3,611	90,022	3,141	Oct 17 05:00 PM
Doyle Katherine C.	Director	Sep 13 '24	Sale	27.30	8,954	244,444	6,009	Sep 13 03:28 PM
Doyle Katherine C.	Director	Sep 13 '24	Proposed Sale	27.30	8,954	244,444		Sep 13 10:03 AM
Janish Ronald Craig	EVP, Gbl Ops & SC & CTO	Aug 26 '24	Sale	29.40	13,000	382,246	20,553	Aug 28 05:17 PM
RONALD CRAIG JANISH	Insider / Exec VP of Global Op	Aug 26 '24	Proposed Sale	29.40	13,000	382,246		Aug 26 04:07 PM
Andersen Svend	EVP & President CHCI	Aug 20 '24	Sale	27.75	28,300	785,279	73,553	Aug 21 09:20 AM
Andersen Svend	EVP & President CHCI	Aug 20 '24	Sale	27.43	6,683	183,281	7,000	Aug 21 09:20 AM
Andersen Svend	Officer	Aug 20 '24	Proposed Sale	27.86	20,500	571,130		Aug 20 01:09 PM
HANSON KYLE	Officer	Aug 07 '24	Proposed Sale	28.40	1,890	53,667		Aug 07 12:02 PM

Dollar change -0.06
Percentage change -4.65	%

ALLO Allogene Therapeutics Inc daily Stock Chart

Peers: NTLA CRSP EDIT BEAM FDMT IOBT SGMO CLLS DTIL CYTK

| Held by: VTI IWM VXF IWN IBB SCHA VTWO VHT DFAS DFAC

Index	RUT	P/E	-	EPS (ttm)	-1.23	Insider Own	31.65%	Shs Outstand	218.60M	Perf Week	-18.54%
Market Cap	269.04M	Forward P/E	-	EPS next Y	-0.99	Insider Trans	-0.29%	Shs Float	149.51M	Perf Month	4.24%
Enterprise Value	77.92M	PEG	-	EPS next Q	-0.27	Inst Own	67.42%	Short Float	17.34%	Perf Quarter	-26.79%
Income	-252.32M	P/S	-	EPS this Y	23.59%	Inst Trans	4.34%	Short Ratio	7.47	Perf Half Y	-33.15%
Sales	0.00M	P/B	0.70	EPS next Y	2.30%	ROA	-46.11%	Short Interest	25.93M	Perf YTD	-42.25%
Book/sh	1.76	P/C	0.96	EPS next 5Y	8.47%	ROE	-59.60%	52W High	3.78 -67.46%	Perf Year	-58.72%
Cash/sh	1.28	P/FCF	-	EPS past 3/5Y	0.45% 6.26%	ROIC	-54.07%	52W Low	0.86 42.67%	Perf 3Y	-90.92%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	-94.22% -	Gross Margin	-	Volatility	8.70% 8.23%	Perf 5Y	-96.81%
Dividend TTM	-	EV/Sales	-	EPS Y/Y TTM	31.43%	Oper. Margin	-	ATR (14)	0.11	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	9.71	Sales Y/Y TTM	-100.00%	Profit Margin	-	RSI (14)	43.75	Recom	1.36
Dividend Gr. 3/5Y	- -	Current Ratio	9.71	EPS Q/Q	27.82%	SMA20	-6.64%	Beta	0.37	Target Price	8.05
Payout	-	Debt/Eq	0.23	Sales Q/Q	-100.00%	SMA50	-3.62%	Rel Volume	1.69	Prev Close	1.29
Employees	229	LT Debt/Eq	0.21	Earnings	May 13 AMC	SMA200	-31.85%	Avg Volume	3.47M	Price	1.23
IPO	Oct 11, 2018	Option/Short	Yes / Yes	EPS/Sales Surpr.	3.61% -100.00%	Trades		Volume	5,850,474	Change	-4.65%

Date	Action	Analyst	Rating Change	Price Target Change
May-14-25	Downgrade	Citizens JMP	Mkt Outperform → Mkt Perform
Mar-14-25	Upgrade	Citizens JMP	Mkt Perform → Mkt Outperform	$5
Aug-08-24	Resumed	Oppenheimer	Outperform	$13 → $11
May-31-24	Initiated	Piper Sandler	Overweight	$11
Jan-05-24	Downgrade	JMP Securities	Mkt Outperform → Mkt Perform
Jan-05-24	Downgrade	Guggenheim	Buy → Neutral
Dec-08-23	Initiated	Citigroup	Buy	$7
Dec-08-23	Initiated	Citigroup	Buy
Jun-26-23	Resumed	Oppenheimer	Outperform	$28
Mar-21-23	Initiated	Bernstein	Mkt Perform	$6
Jan-24-23	Upgrade	JP Morgan	Neutral → Overweight	$20 → $11
Jan-06-23	Upgrade	Robert W. Baird	Neutral → Outperform	$12
Dec-12-22	Downgrade	BofA Securities	Buy → Underperform	$24 → $9
Aug-10-22	Downgrade	Raymond James	Outperform → Mkt Perform
Jul-15-22	Upgrade	Goldman	Neutral → Buy	$9 → $32
Jun-03-22	Initiated	Robert W. Baird	Neutral	$11
Feb-28-22	Reiterated	B. Riley Securities	Buy	$30 → $21
Oct-20-21	Initiated	Cowen	Outperform
Oct-08-21	Downgrade	Stifel	Buy → Hold	$44 → $18
Oct-08-21	Downgrade	Goldman	Buy → Neutral	$71 → $20

Show Previous Ratings

Jul-23-25 09:26AM	High-Growth Oncology Market Projected For US$900bn in Revenue Despite Policy Headwinds (PR Newswire) +16.90%
Jul-21-25 09:41AM	Betting Big on Cancer: 3 Oncology Stocks Set to Surge in 2025 (Zacks) +5.60%
Jun-12-25 11:30AM	Why Is Allogene Therapeutics (ALLO) Up 52.2% Since Last Earnings Report? (Zacks)
Jun-04-25 12:00PM	All You Need to Know About Allogene Therapeutics (ALLO) Rating Upgrade to Buy (Zacks)
Jun-01-25 10:45AM	Allogene Therapeutics Provides Updated Phase 1 Data Highlighting Durable Responses with ALLO-316 in Heavily Pretreated Advanced Renal Cell Carcinoma at ASCO (GlobeNewswire)
08:30AM	Loading…
May-23-25 08:30AM	Allogene Therapeutics Announces Participation in Upcoming Investor Conferences (GlobeNewswire)
May-22-25 05:17PM	Allogene Therapeutics Announces ASCO 2025 Abstract Publication Featuring Oral Presentation of ALLO-316 in Kidney Cancer and ALPHA3 TIP Poster for Cema-Cel (GlobeNewswire)
May-20-25 09:11AM	REGN Signs $256M Buyout Deal With 23andMe to Boost Genomics Research (Zacks) +6.42%
May-16-25 06:36AM	Regeneron defeats Amgen in PCSK9 case; 2 cell therapy biotechs cut staff (BioPharma Dive)
May-15-25 11:04AM	Kodiak Q1 Loss Wider Than Expected, Pipeline Development in Focus (Zacks) +14.40%
09:43AM	Allogene (ALLO) Sinks 16% on Downgrade, Trial Delays (GuruFocus.com)
09:35AM	Allogene Therapeutics (ALLO) Loses -31.94% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner (Zacks)
May-14-25 11:41AM	Fate Therapeutics' Q1 Earnings & Revenues Beat, Pipeline in Focus (Zacks) -15.68%
10:46AM	Q1 2025 Allogene Therapeutics Inc Earnings Call (Thomson Reuters StreetEvents)
09:00AM	EXEL Q1 Earnings Beat, 2025 Sales View Up as Cabometyx Drives Top Line (Zacks)
06:29AM	Loading…
06:29AM	Allogene's Q1 Earnings In Line With Estimates, Sales Nil (Zacks)
03:18AM	Allogene Therapeutics Inc (ALLO) Q1 2025 Earnings Call Highlights: Strategic Advances Amid ... (GuruFocus.com)
May-13-25 04:11PM	Allogene Therapeutics: Q1 Earnings Snapshot (Associated Press Finance)
04:05PM	Allogene Therapeutics Reports First Quarter 2025 Financial Results and Business Update (GlobeNewswire)
12:07PM	Xenon Q1 Loss Narrower Than Expected, Pipeline Development in Focus (Zacks)
08:42AM	Editas Q1 Loss Narrower Than Expected, Revenues Increase Y/Y (Zacks)
May-12-25 09:40AM	Allogene Therapeutics Inc (ALLO) Q1 2025 Earnings Report Preview: What To Look For (GuruFocus.com)
09:20AM	RDY Q4 Earnings Beat Estimates, Generics Revenues Rise Y/Y, Stock Up (Zacks)
May-09-25 08:26AM	Is Allogene Therapeutics, Inc. (ALLO) the Low Risk High Reward Stock Set to Triple by 2030? (Insider Monkey)
May-06-25 08:30AM	Allogene Therapeutics to Report First Quarter 2025 Financial Results and Provide Business Update (GlobeNewswire) -20.99%
Apr-23-25 10:12AM	Allogene Therapeutics to Present Updated ALLO-316 Clinical Results in Kidney Cancer in Oral Presentation and ALPHA3 Trial-in-Progress Poster for Cema-Cel at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting (GlobeNewswire)
Apr-08-25 06:46AM	FDA Grants Three Fast Track Tags to Allogene's Autoimmune Disease Drug (Zacks)
Apr-07-25 08:30AM	Allogene Granted Three U.S. FDA Fast Track Designations (FTD) for ALLO-329, a Next-Generation Dual-Targeted CD19/CD70 Allogeneic CAR T, for the Treatment of Lupus, Myositis and Scleroderma (GlobeNewswire)
Mar-30-25 03:50AM	abrdn Life Sciences Investors Q4 2024 Commentary (Seeking Alpha)
Mar-14-25 03:00PM	Allogene Therapeutics Inc (ALLO) Q4 2024 Earnings Call Highlights: Financial Challenges Amid ... (GuruFocus.com)
04:11PM	Loading…
Mar-13-25 04:11PM	Allogene Therapeutics: Q4 Earnings Snapshot (Associated Press Finance) -8.25%
04:02PM	Allogene Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Business Update (GlobeNewswire)
Mar-03-25 08:30AM	Allogene Therapeutics to Report Fourth Quarter and Full Year 2024 Financial Results and Provide Business Update (GlobeNewswire) -7.69%
Feb-26-25 08:30AM	Allogene Therapeutics Announces Participation in March Investor Conference (GlobeNewswire)
Feb-25-25 04:10PM	Allogene Therapeutics Expands Strategic Partnership with Foresight Diagnostics to Advance Joint Development Activities Outside the US Across Europe, UK, Canada, and Australia (GlobeNewswire) -7.24%
Feb-13-25 04:30PM	Allogene Therapeutics Announces Publication of Durable Response Data from Phase 1 ALPHA/ALPHA2 Trials of the Allogeneic CAR T Cemacabtagene Ansegedleucel/ALLO-501 in Relapsed/Refractory Large B-Cell Lymphoma in the Journal of Clinical Oncology (GlobeNewswire) +44.68%
Feb-04-25 08:30AM	Allogene Therapeutics Announces Participation in February Investor Conferences (GlobeNewswire)
Jan-29-25 08:30AM	Allogene Therapeutics Announces Benjamin M. Beneski as Senior Vice President and Chief Technical Officer (GlobeNewswire)
Jan-28-25 08:30AM	Allogene Therapeutics Secures U.S. FDA IND Clearance for ALLO-329, Advancing its Next-Generation Allogeneic CAR T into Autoimmune Diseases (GlobeNewswire)
Dec-26-24 12:00PM	Allogene Therapeutics (ALLO) Upgraded to Buy: What Does It Mean for the Stock? (Zacks)
11:26AM	Oncology in Focus: How Emerging Therapies Are Reshaping Cancer Treatment (PR Newswire)
Dec-16-24 08:30AM	Allogene Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference (GlobeNewswire) +8.99%
Dec-12-24 08:30AM	Allogene Therapeutics Acknowledges the Passing of Founding Board Member David Bonderman (GlobeNewswire) -5.61%
Nov-25-24 12:00PM	Allogene Therapeutics (ALLO) Upgraded to Buy: Here's Why (Zacks)
Nov-19-24 08:30AM	Allogene Therapeutics Announces Participation in December Investor Conferences (GlobeNewswire)
Nov-18-24 08:30AM	Allogene Therapeutics Presents Preclinical Data for ALLO-329, an Allogeneic CD19/CD70 Dual CAR T for the Treatment of Autoimmune Disease at the American College of Rheumatology (ACR) Convergence (GlobeNewswire) -5.29%
Nov-08-24 06:07AM	Allogene Therapeutics Inc (ALLO) Q3 2024 Earnings Call Highlights: Financial Resilience Amidst ... (GuruFocus.com)
Nov-07-24 04:11PM	Allogene Therapeutics: Q3 Earnings Snapshot (Associated Press Finance)
04:02PM	Allogene Therapeutics Reports Third Quarter 2024 Financial Results and Business Update (GlobeNewswire)
10:00AM	Allogene Therapeutics Announces Positive Phase 1 Data Demonstrating the Potential of ALLO-316 in Heavily Pretreated Patients with Advanced Renal Cell Carcinoma at SITC and IKCS (GlobeNewswire)
Nov-06-24 07:31AM	Allogene Therapeutics Inc (ALLO) Q3 2024: Everything You Need To Know Ahead Of Earnings (GuruFocus.com) +7.69%
Nov-05-24 09:10AM	Allogene Therapeutics to Present New Data Demonstrating the Potential of ALLO-316 in Heavily Pretreated Adult Patients with CD70 Positive Advanced Renal Cell Carcinoma (RCC) at the International Kidney Cancer Symposium (IKCS) and Society for Immunotherapy of Cancer (SITC) Annual Meeting (GlobeNewswire)
Nov-04-24 08:30AM	Allogene Therapeutics Announces Participation in November Investor Conferences (GlobeNewswire) +10.29%
Oct-31-24 10:01AM	Will Allogene Therapeutics (ALLO) Report Negative Earnings Next Week? What You Should Know (Zacks)
Oct-30-24 08:30AM	Allogene Therapeutics to Report Third Quarter 2024 Financial Results and Provide Business Update (GlobeNewswire) -5.71%
Oct-29-24 08:30AM	Allogene Therapeutics Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for ALLO-316, an AlloCAR T Investigational Product for Adult Patients with Advanced or Metastatic Renal Cell Carcinoma (RCC) (GlobeNewswire)
Oct-22-24 04:05PM	Artiva Biotherapeutics Appoints Alison Moore, Ph.D., to Its Board of Directors (GlobeNewswire)
Oct-03-24 07:19AM	Allogene Therapeutics, Inc. (ALLO): Among the Rising Penny Stocks to Invest In Now (Insider Monkey)
Sep-30-24 08:30AM	Allogene Therapeutics Announces Participation in the Goldman Sachs Cell Therapy Day Conference (GlobeNewswire)
Sep-26-24 08:30AM	Allogene Therapeutics to Present Pre-Clinical Data Highlighting the Potential of ALLO-329, an Allogeneic CD19/CD70 Dual CAR T for the Treatment of Autoimmune Diseases, at the American College of Rheumatology (ACR) Convergence (GlobeNewswire)
Sep-14-24 05:39PM	Allogene Therapeutics, Inc. (ALLO): Short Seller Sentiment is Bearish on This Cancer Stock (Insider Monkey)
Sep-06-24 11:31AM	Allogene Therapeutics (ALLO) Up 6.4% Since Last Earnings Report: Can It Continue? (Zacks)
Aug-08-24 09:50AM	Allogene (ALLO) Posts Narrower Than Expected Loss in Q2 (Zacks)
08:30AM	Allogene Therapeutics Announces Participation in Upcoming Investor Conferences (GlobeNewswire)
06:00AM	7 Biotech Stocks to Buy for Their Game-Changing Potential (InvestorPlace)
Aug-07-24 04:10PM	Allogene Therapeutics: Q2 Earnings Snapshot (Associated Press Finance)
04:02PM	Allogene Therapeutics Reports Second Quarter 2024 Financial Results and Business Update (GlobeNewswire)
Jul-31-24 08:30AM	Allogene Therapeutics to Report Second Quarter 2024 Financial Results and Provide Business Update (GlobeNewswire)
Jul-01-24 08:30AM	Allogene Therapeutics Activates Three Community Cancer Centers as First Sites for the Pivotal Phase 2 ALPHA3 Trial Evaluating Cemacabtagene Ansegedleucel (cema-cel) as First Line (1L) Consolidation Treatment for Patients with Large B-Cell Lymphoma (LBCL) (GlobeNewswire)
Jun-27-24 10:13AM	Allogene Therapeutics, Inc. (ALLO): Are Analysts Bullish About the Potential of This Small-Cap Stock? (Insider Monkey)
Jun-26-24 04:36PM	Top 10 Small-Cap Stocks with Highest Upside Potential (Insider Monkey)
Jun-20-24 08:30AM	Allogene Therapeutics Initiates Pivotal Phase 2 Trial Investigating Cemacabtagene Ansegedleucel (cema-cel), an Allogeneic CAR T Product, as Part of First Line Treatment for Patients with Large B-Cell Lymphoma (LBCL) Likely to Relapse (GlobeNewswire) +9.42%
Jun-12-24 11:30AM	Allogene Therapeutics (ALLO) Down 13.9% Since Last Earnings Report: Can It Rebound? (Zacks)
May-29-24 08:55AM	Insiders Pour Millions Into These 2 Strong Buy Stocks (TipRanks)
May-28-24 04:05PM	If You Can Only Buy One Penny Stock in May, It Better Be One of These 3 Names (InvestorPlace)
May-23-24 08:30AM	Allogene Therapeutics Announces Participation in the TD Cowen 5th Annual Oncology Innovation Summit (GlobeNewswire)
May-21-24 01:56PM	Hedge Fund and Insider Trading News: Ken Griffin, Sanjay Shah, David Tepper, Stanley Druckenmiller, Michael Burry, Cevian Capital, Elliott Management, Millennium Management, Eisler Capital, Allogene Therapeutics Inc (ALLO), Carvana Co. (CVNA) and More (Insider Monkey)
08:16AM	Oppenheimer Trims Allogene Therapeutics Price Target to $13 From $14, Maintains Outperform Rating (MT Newswires)
May-16-24 08:13AM	HC Wainwright Adjusts Price Target on Allogene Therapeutics to $9 From $10, Keeps Buy Rating (MT Newswires)
May-14-24 12:56PM	Allogene (ALLO) Q1 Earnings in Line With Estimates, Sales Lag (Zacks)
09:14AM	Stifel Adjusts Price Target on Allogene Therapeutics to $4.60 From $4.40, Keeps Hold Rating (MT Newswires)
08:21AM	B. Riley Adjusts Price Target on Allogene Therapeutics to $7 From $10, Keeps Buy Rating (MT Newswires)
03:06AM	Allogene Therapeutics Inc (ALLO) (Q1 2024) Earnings Call Transcript Highlights: Strategic ... (GuruFocus.com)
May-13-24 08:55PM	ALLO Stock Earnings: Allogene Therapeutics Beats EPS, Beats Revenue for Q1 2024 (InvestorPlace) +5.07%
05:36PM	Allogene Therapeutics Prices $110 Million Offering (MT Newswires)
05:10PM	Allogene Therapeutics (ALLO) Reports Q1 Loss, Lags Revenue Estimates (Zacks)
04:47PM	Allogene Therapeutics Announces Pricing of $110 million Offering of Common Stock (GlobeNewswire)
04:17PM	Allogene Therapeutics: Q1 Earnings Snapshot (Associated Press Finance)
04:14PM	Allogene Therapeutics Q1 Loss Narrows, Revenue Declines (MT Newswires)
04:01PM	Allogene Therapeutics Reports First Quarter 2024 Financial Results and Business Update (GlobeNewswire)
May-06-24 08:30AM	Allogene Therapeutics to Report First Quarter Financial Results and Provide Business Update (GlobeNewswire)
Apr-26-24 10:32AM	Allogene Therapeutics Gets $15 Million Grant from California Institute for Regenerative Medicine for Cancer Drug Development (MT Newswires)
08:30AM	Allogene Therapeutics Awarded Grant from the California Institute for Regenerative Medicine to Advance Development of an Allogeneic CAR T in Renal Cell Carcinoma (GlobeNewswire)
Apr-24-24 10:01AM	Allogene Therapeutics (ALLO) Expected to Beat Earnings Estimates: Should You Buy? (Zacks) -9.79%
Apr-11-24 02:45PM	3 Meme Stocks to Sell and Replace With Meme Coins (InvestorPlace)
Apr-09-24 08:30AM	Allogene Therapeutics Announces Q2 Investor Conference Participation (GlobeNewswire)
Apr-08-24 08:46AM	How Allogene (ALLO) Stock Stands Out in a Strong Industry (Zacks)
Mar-16-24 04:35PM	Allogene Therapeutics, Inc. (NASDAQ:ALLO) Q4 2023 Earnings Call Transcript (Insider Monkey)
Mar-15-24 09:32AM	Allogene's (ALLO) Q4 Loss Narrower Than Expected, Sales Miss (Zacks)
07:04AM	Q4 2023 Allogene Therapeutics Inc Earnings Call (Thomson Reuters StreetEvents)

Allogene Therapeutics, Inc. operates as a clinical stage immuno-oncology company pioneering the development and commercialization of genetically engineered allogeneic T cell therapies for the treatment of cancer. The firm develops a pipeline of off-the-shelf T cell product candidates that are designed to target and kill cancer cells. Its engineered T cells are allogeneic, which are derived from healthy donors for intended use in any patient. The company was founded by Arie S. Belldegrun, David D. Chang, David M. Tanen, and Joshua A. Kazam in November 2017 and is headquartered in South San Francisco, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
MESSEMER DEBORAH M.	Director	Jun 10 '25	Sale	1.42	36,885	52,377	107,431	Jun 12 04:18 PM
MESSEMER DEBORAH M.	Director	Jun 10 '25	Proposed Sale	1.42	36,885	52,391		Jun 10 04:29 PM
Yoshiyama Annie	SVP, Finance	Apr 21 '25	Sale	1.41	9,601	13,537	130,663	Apr 23 05:28 PM
Yoshiyama Annie	Officer	Apr 21 '25	Proposed Sale	1.41	9,601	13,537		Apr 21 04:49 PM
Chang David D	President and CEO	Mar 14 '25	Sale	1.96	46,668	91,469	5,276,569	Mar 18 05:30 PM
Beneski Benjamin Machinas	SVP, Chief Technical Officer	Mar 14 '25	Sale	1.98	5,488	10,839	218,507	Mar 18 05:28 PM
Beneski Benjamin Machinas	Officer	Mar 14 '25	Proposed Sale	1.97	5,488	10,839		Mar 14 04:58 PM
Chang David D	Officer	Mar 14 '25	Proposed Sale	1.96	46,668	91,469		Mar 14 04:57 PM
MESSEMER DEBORAH M.	Director	Feb 18 '25	Sale	2.43	13,313	32,351	144,316	Feb 20 04:15 PM
MESSEMER DEBORAH M.	Director	Feb 18 '25	Proposed Sale	2.43	13,313	32,329		Feb 18 05:27 PM
Douglas Earl Martin	SVP, General Counsel	Feb 03 '25	Sale	1.71	6,404	10,951	587,848	Feb 05 04:16 PM
Parker Geoffrey M.	CHIEF FINANCIAL OFFICER	Feb 03 '25	Sale	1.73	4,361	7,545	1,301,540	Feb 05 04:15 PM
MOORE TIMOTHY L.	Chief Technical Officer	Feb 03 '25	Sale	1.71	14,746	25,216	250,713	Feb 05 04:14 PM
Chang David D	President and CEO	Feb 03 '25	Sale	1.68	46,003	77,285	5,317,237	Feb 05 04:13 PM
Roberts Zachary	EVP of R&D	Feb 03 '25	Sale	1.70	18,832	32,014	643,135	Feb 05 04:12 PM
Roberts Zachary	Officer	Feb 03 '25	Proposed Sale	1.70	18,832	32,014		Feb 03 04:32 PM
Chang David D	Officer	Feb 03 '25	Proposed Sale	1.68	46,003	77,446		Feb 03 04:31 PM
Douglas Earl Martin	Officer	Feb 03 '25	Proposed Sale	1.71	6,404	10,951		Feb 03 04:30 PM
MOORE TIMOTHY L.	Officer	Feb 03 '25	Proposed Sale	1.71	14,746	25,225		Feb 03 04:29 PM
Parker Geoffrey M.	Officer	Feb 03 '25	Proposed Sale	1.73	4,361	7,545		Feb 03 04:28 PM
Roberts Zachary	EVP of R&D	Jan 21 '25	Sale	1.78	27,199	48,414	488,054	Jan 23 04:30 PM
Roberts Zachary	Officer	Jan 21 '25	Proposed Sale	1.78	27,199	48,499		Jan 21 04:22 PM
MESSEMER DEBORAH M.	Director	Dec 09 '24	Sale	2.18	9,136	19,916	157,629	Dec 10 04:53 PM
Humer Franz B	Director	Dec 05 '24	Sale	2.16	9,221	19,917	307,507	Dec 09 04:05 PM
MESSEMER DEBORAH M.	Director	Dec 09 '24	Proposed Sale	2.18	9,136	19,954		Dec 09 04:02 PM
Humer Franz B	Director	Dec 03 '24	Proposed Sale	2.48	9,221	22,868		Dec 02 02:11 PM
Parker Geoffrey M.	Officer	Oct 21 '24	Proposed Sale	2.84	36,404	103,501		Oct 21 04:05 PM
Douglas Earl Martin	Officer	Aug 21 '24	Proposed Sale	2.79	28,310	78,844		Aug 21 04:18 PM

PRGO

Perrigo Company plc

ALLO

Allogene Therapeutics Inc

Upgrade your FINVIZ experience